Skip to content

Caribbean and South America Team-based Strategy to Control Hypertension

Implementing and Scaling Up a Team-based Care Strategy for Hypertension Control in Colombia and Jamaica

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05405920
Acronym
CATCH
Enrollment
1280
Registered
2022-06-06
Start date
2023-02-01
Completion date
2026-08-31
Last updated
2024-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure, Hypertension

Brief summary

The CATCH cluster randomized trial will test the implementation and effectiveness outcomes of implementing and scaling up a team-based care strategy for blood pressure control in Colombia and Jamaica.

Detailed description

The CATCH Study includes a two-year UG3 Planning Phase and a four-year UH3 Implementation Phase. In the UH3 Implementation Phase, we will first conduct a cluster randomized implementation trial to test the effectiveness and implementation of a team-based care strategy for hypertension control among patients with hypertension in 40 clinics from Colombia and Jamaica (20 in each country). Twenty clinics will be randomized to the team-based care intervention and 20 to provider training intervention. A total of 1,680 patients (42 per clinic) with uncontrolled hypertension will be recruited into the study and followed for 18 months for effectiveness and implementation outcomes. A post-intervention study visit will take place 6 months after the end of the 18-month intervention to evaluate the sustainability of the implementation strategies. We will subsequently conduct a pre- and post- scale-up comparison study to implement the team-based care strategy in all remaining public primary care clinics that provide chronic disease management in Jamaica and primary care clinics in the seven participating departments in Colombia. A pre- and post- scale-up comparison design will be used to assess barriers and implementation outcomes before and 12 months after the scale-up intervention at the clinic, primary care physician, nurse/pharmacist, and community health worker (CHW) levels.

Interventions

BEHAVIORALTeam-based Care Strategy for Hypertension Control

The core component of the intervention is a stepped-care protocol, based on the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Clinical Practice Guideline for High Blood Pressure and the 2021 World Health Organization (WHO) Hypertension Guideline. Using a team-based care model, a physician-nurse-CHW team will work with patients to implement clinical guideline-based treatment in all intervention clinics. Team-based care components will include task sharing and shifting, health care team training, home BP monitoring, BP audit and feedback, and CHW-led health coaching on lifestyle modification and medication adherence.

BEHAVIORALEnhanced Usual Care

We will train the primary care physicians, nurses, and other clinic staff in performing standardized BP measurements. We will offer physician education on clinical guidelines for hypertension management and issue continuing medical education credits. Patient educational materials will be distributed. We will not conduct any other interventions in the enhanced usual care clinics.

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
Universidad de Santander
CollaboratorOTHER
University of the West Indies, Jamaica
CollaboratorUNKNOWN
Tulane University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

Due to the nature of the cluster design and intervention program, the study participants, primary care physicians, nurses, community health workers, and research staff who collected clinical outcome data will not be blinded. The outcome adjudication committee members, however, will be blinded to randomization assignment for adverse event evaluation.

Intervention model description

cluster-randomization of 40 primary care clinics

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

for clinics: * Serving \>300 hypertensive patients during the previous year * Clinic visits and BP medications are free of charge to patients * Not sharing physicians, nurses, pharmacists, or community health workers (CHWs) with other clinics Inclusion criteria for participants: * Men or women aged ≥ 21 years who receive primary care from participating clinics * Average untreated BP ≥140/90 mm Hg among individuals without a history of clinical cardiovascular disease (CVD), chronic kidney disease (CKD), or diabetes; average untreated BP ≥130/80 mm Hg among individuals aged ≥65 years or those with clinical CVD, CKD, or diabetes; or average treated BP ≥130/80 mm Hg from six BP readings at two screening visits * Not pregnant or planning to become pregnant in the next 18 months * Able and willing to give informed consent * No plans to change primary care clinic in the next 18 months * Not an immediate family member of staff at the primary care clinic

Design outcomes

Primary

MeasureTime frameDescription
Net difference in mean change of systolic blood pressure18 monthsDifferences in mean change of systolic BP from baseline to 18 months between intervention and control groups

Secondary

MeasureTime frameDescription
Difference in blood pressure control (<130/80 mm Hg)18 monthsDifference in the proportion of patients with systolic BP \<130 mm Hg and diastolic BP \<80 mm Hg between intervention and control groups at 18 months
Net difference in mean change of diastolic blood pressure18 monthsDifferences in mean change of diastolic BP from baseline to 18 months between intervention and control groups
Side effects18 monthsDifferences in medication side effects between intervention and control groups will be assessed by survey. A list of common side effects associated with high blood pressure will be asked of participants to collect presence and frequency of side effects.
Health-related quality of life18 monthsDifferences in health-related quality of life (measured by EQ-SD and SF-12) between intervention and control groups
Cost-effectiveness18 monthsIncremental direct costs per additional percentage of hypertension control

Other

MeasureTime frameDescription
Penetrance18 monthsDefined as % of providers using the intervention approach
Acceptability18 monthsMeasured by validated survey
Sustainability18 months% of clinics maintaining intervention
AdoptionBaselineDefined as % of clinics adopting intervention components
Appropriateness18 monthsMeasured by validated survey
Feasibility (suitability)BaselineMeasured by validated survey
Fidelity18 months% of each intervention component delivered per protocol
Implementation Costs18 monthsDefined as all costs associated with implementation and assessed from administrative data

Countries

Colombia, Jamaica

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026